Year Founded
1997
Ownership
Public
Employees
~250
Stage
Phase 3
Modalities
NanomedicineLiposome formulationLipid nanoparticles (LNP)Gene therapy

TLC BioSciences General Information

Lead candidate TLC599 showed sustained clinical benefits to 24 weeks in Phase 3 for osteoarthritis knee pain, with second injection extending benefits to 52 weeks. Recently secured marketing approval for Ampholipad in China.

Contact Information

Website
Primary Industry
Biotech
Corporate Office
South San Francisco, California
United States

Drug Pipeline

TLC599
Phase 3
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 2
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 3
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum

For full access to TLC BioSciences's pipeline data

Book a demo

Key Partnerships

Endo, Zydus

Need more data on over 80,000 life science companies, including over 1200 biotechs?

Book a demo

TLC BioSciences Funding

Deal TypeDateAmountStatusStage
Early Stage VC (Series A)04-Jun-2020$38MCompletedPhase 1
Seed Round12-Feb-2019$8.5MCompletedStartup

Interested in comprehensive profile data?

We'll help you find what you need

Learn more
To view TLC BioSciences's complete valuation and funding history, request access »